tiprankstipranks
Moonlake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market
MLTX
MoonLake Immunotherapeutics
RESEARCH TOOLSreports
Want to see MLTX full AI Analyst Report?

MoonLake Immunotherapeutics (MLTX) Stock News & Sentiment

650 Followers
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
Premium
Ratings
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
8d ago
MLTX
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
Premium
Ratings
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
9d ago
MLTX
MoonLake advances sonelokimab toward BLA after positive FDA meeting
Premium
Company Announcements
MoonLake advances sonelokimab toward BLA after positive FDA meeting
9d ago
8K
MLTX
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
Premium
Ratings
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
1M ago
MLTX
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
Premium
Ratings
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
1M ago
MLTX
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
Premium
Ratings
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
1M ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
Premium
Ratings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
2M ago
MLTX
More MLTX News >

MLTX News on the Web

LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
TipRanks News
Neutral
Insider Sell Alert: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX)
GuruFocus News
Neutral
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
TipRanks News
Neutral
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: SI-Bone (SIBN) and MoonLake Immunotherapeutics (MLTX)
TipRanks News
Neutral
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Evolent Health (EVH), MoonLake Immunotherapeutics (MLTX) and CAMP4 Therapeutics Corporation (CAMP)
TipRanks News
Neutral
Goldman Sachs Keeps Their Sell Rating on MoonLake Immunotherapeutics (MLTX)
TipRanks News
Bearish

News Score - Last 7 Days

Very Positive
MLTX
Sector Average
Media Buzz
This Week2 articles
Weekly Average4.25 articles
News Sentiment
This Week59%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MLTX’s Media Buzz Sentiment?
2 articles about MLTX were published this week. In an average week, 4.25 articles are published.
    What is MLTX’s weekly average amount of articles?
    In an average week, 4.25 articles about MLTX are published.
      What is MLTX’s News Sentiment?
      59% of articles about MLTX were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        DOCSDoximity
        AVAHAveanna Healthcare Holdings
        GOSSGossamer Bio
        CGENCompugen
        RLAYRelay Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week